| Literature DB >> 33235942 |
Marcos Amaku1,2, Dimas Tadeu Covas3, Francisco Antonio Bezerra Coutinho1, Raymundo Soares Azevedo Neto1, Claudio Struchiner4, Annelies Wilder-Smith5,6,7, Eduardo Massad1,4.
Abstract
Testing for detecting the infection by SARS-CoV-2 is the bridge between the lockdown and the opening of society. In this paper we modelled and simulated a test-trace-and-quarantine strategy to control the COVID-19 outbreak in the State of São Paulo, Brasil. The State of São Paulo failed to adopt an effective social distancing strategy, reaching at most 59% in late March and started to relax the measures in late June, dropping to 41% in 08 August. Therefore, São Paulo relies heavily on a massive testing strategy in the attempt to control the epidemic. Two alternative strategies combined with economic evaluations were simulated. One strategy included indiscriminately testing the entire population of the State, reaching more than 40 million people at a maximum cost of 2.25 billion USD, that would reduce the total number of cases by the end of 2020 by 90%. The second strategy investigated testing only symptomatic cases and their immediate contacts - this strategy reached a maximum cost of 150 million USD but also reduced the number of cases by 90%. The conclusion is that if the State of São Paulo had decided to adopt the simulated strategy on April the 1st, it would have been possible to reduce the total number of cases by 90% at a cost of 2.25 billion US dollars for the indiscriminate strategy but at a much smaller cost of 125 million US dollars for the selective testing of symptomatic cases and their contacts.Entities:
Keywords: COVID-19; Cost-analysis; Modelling; SARS-CoV-2; Testing
Year: 2020 PMID: 33235942 PMCID: PMC7677040 DOI: 10.1016/j.idm.2020.11.004
Source DB: PubMed Journal: Infect Dis Model ISSN: 2468-0427
Fig. 1Schematic representation of the model compartments.
Parameters used in the model.
| Parameter | Description | Value |
|---|---|---|
| Potentially infective contact rate | Fitted (changes over time) | |
| Infectivity of exposed individuals | 0.4 | |
| Infectivity of symptomatic individuals | 1.0 | |
| Infectivity of asymptomatic individuals | 1/3 | |
| Infectivity of hospitalized individuals | 0.01 | |
| Infectivity of ICU patients | 0.01 | |
| Natural mortality rate (life expectancy of 70 years) | 3.91 × 10−5 days−1 | |
| Rate of evolution from exposed to infected | 1/2 day−1 | |
| Rate of evolution from exposed to asymptomatic | 1.45 day−1 | |
| Rate of recovery from infected | 1/3 day−1 | |
| Rate of recovery from asymptomatic | 1/14 day−1 | |
| Rate of recovery from hospitalized | 1/10 day−1 | |
| Rate of recovery from ICU | 0.06752 day−1 | |
| Rate of recovery from isolated | 1/14 day−1 | |
| Disease-induced mortality rate for infected individuals | 5 × 10−4 day−1 | |
| Disease-induced mortality rate for asymptomatic individuals | 0 | |
| Disease-induced mortality rate for hospitalized individuals | 2.2012 × 10−4 day−1 | |
| Disease-induced mortality rate for ICU patients | Fitted (changes over time) | |
| Testing rate of susceptible individuals | Variable | |
| Testing rate of exposed individuals | Variable | |
| Testing rate of symptomatic individuals | Variable | |
| Testing rate of asymptomatic individuals | Variable | |
| Hospitalization rate | 1.973 × 10−2 day−1 | |
| ICU admission rate | Fitted (changes over time) | |
| Notification ratio | Fitted (changes over time) | |
| Birth rate | Changes over time |
Assumed.
Fitted.
Fig. 2Cumulative number of reported cases and deaths (black dots in (a) and (b), respectively) and the corresponding fitted model (blue lines). The solid lines and shaded area correspond, respectively, to median values and 95% probability intervals.
Fig. 3Results for the strategy that considers testing susceptible and infected (symptomatic and asymptomatic) individuals showing the evolution of the testing strategy efficacy (1 minus the number of cumulative cases under a specific testing strategy up to December 31, 2020 divided by the number of cases when no test is used) as a function of the total number of tests (a) and corresponding costs in US dollars (b) for different dates of start. Each dot corresponds to a different daily testing rate and the dot size is proportional to the testing rate.
Fig. 4Results for the strategy that considers testing infected (symptomatic and asymptomatic) individuals showing the evolution of the testing strategy efficacy (1 minus the number of cumulative cases under a specific testing strategy up to December 31, 2020 divided by the number of cases when no test is used) as a function of the total number of tests (a) and corresponding costs in US dollars (b) for different dates of start. Each dot corresponds to a different daily testing rate and the dot size is proportional to the testing rate.
Fig. 5Results for the strategy that considers testing infected (symptomatic and asymptomatic) individuals showing the evolution of the testing strategy efficacy (1 minus the number of cumulative cases under a specific testing strategy up to December 31, 2020 divided by the number of cases when no test is used) as a function of the daily testing rate for different dates of start. The dot size is proportional to the testing rate.
Fig. 6Total number of tests over time and the corresponding number of cumulative cases for two different daily testing rates (0.5% and 2.1% per day) for mass testing starting on April 1st.